{"schema_version":"secwatch.filing_event.v1","accession":"0001200375-24-000020","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.361519+00:00","generated_at":"2026-05-31T10:42:04.210225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Codexis Q2 revenues fall 62% YoY to $8.0M; net loss widens; reiterates FY2024 guidance","bullets":["Q2 total revenue $8.0M vs $21.3M YoY; product rev $6.3M vs $11.0M; R&D rev $1.7M vs $10.3M.","Net loss $22.8M ($0.32/sh) vs $11.5M ($0.17/sh); product gross margin 45% vs 71%.","Cash $73.2M; expects to fund operations through positive cash flow around end-2026.","FY2024 guidance reiterated: product rev $38-42M (ex-PAXLOVID), R&D rev $18-22M, product GM 58-63%.","Received low-to-mid single-digit million-dollar dsRNA ligase order; expects first ECO Synthesis collaboration by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001200375-24-000020","json":"https://secwatch.observer/filing/0001200375-24-000020.json","markdown":"https://secwatch.observer/filing/0001200375-24-000020.md","text":"https://secwatch.observer/filing/0001200375-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000120037524000020/0001200375-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000120037524000020/cdxs-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:42:04.210225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}